Review



vstx3  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Alomone Labs vstx3
    Vstx3, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vstx3/product/Alomone Labs
    Average 90 stars, based on 3 article reviews
    vstx3 - by Bioz Stars, 2026-02
    90/100 stars

    Images



    Similar Products

    vstx3  (Alomone Labs)
    90
    Alomone Labs vstx3
    Vstx3, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vstx3/product/Alomone Labs
    Average 90 stars, based on 1 article reviews
    vstx3 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    inhibitors  (Alomone Labs)
    90
    Alomone Labs inhibitors
    (A) NaV isoform selectivity of <t>inhibitors</t> GX-674 at 500 nM (orange; NaV1.2/1.6/1.7 and NaV1.5-GX), VSTx3 at 500 nM (green; NaV1.3/1.7/1.8), TTX at 50 nM (dark blue; NaV1.1/1.2/1.3/1.4/1.6/1.7), and μ-Conotoxin GIIIB at 200 nM (light blue; NaV1.4). (B) Average current density is similar in left and right ventricles but higher in the atria. Data from pooled WT and NaV1.5-GX cardiomyocytes (LV, n=13; RV, n=9; atria, n=18). Mean ± SD; ***, p<0.001; ****, p<0.0001; one-way ANOVA with post-hoc Tukey’s test. (C) Representative diary plots of peak current density and current traces (insets) of sodium currents during cumulative serial application of NaV inhibitors in isolated mouse cardiomyocytes from left ventricle (left), right ventricle (middle), and atria (right). Cells were held at a potential of -80 mV, hyperpolarized to -120 mV for 100 ms, and depolarized to -20 mV for 300 ms to elicit peak currents at 1 Hz in 50 mM Na + external solution. Scale bars in insets represent 5 nA (vertical) and 3 ms (horizontal). Bars above each plot indicate the application of NaV inhibitor at the concentrations described above. Experiments targeting NaV1.4, NaV1.1/1.3, and NaV1.8 in ventricle (middle left, bottom left) were performed in 140 mM Na + external solution in the presence of 500 nM GX-674 at baseline to amplify current from the target isoforms. (D) Estimated percent of the baseline sodium current attributable to each NaV isoform in LV, RV, and atria. Percentages of NaV1.4, NaV1.1/1.3, and NaV1.8 were scaled according to the average non-NaV1.5 and non-NaV1.2/1.6/1.7 current. Mean ± SD. Sample sizes are indicated above each bar. N ≥ 6 mice per heart chamber. (E) Summary of sodium current composition by NaV isoform in LV, RV, and atria. Legend as in panel D.
    Inhibitors, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/inhibitors/product/Alomone Labs
    Average 90 stars, based on 1 article reviews
    inhibitors - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    voltage sensor toxin 3 vstx3  (Alomone Labs)
    90
    Alomone Labs voltage sensor toxin 3 vstx3
    (A) NaV isoform selectivity of <t>inhibitors</t> GX-674 at 500 nM (orange; NaV1.2/1.6/1.7 and NaV1.5-GX), VSTx3 at 500 nM (green; NaV1.3/1.7/1.8), TTX at 50 nM (dark blue; NaV1.1/1.2/1.3/1.4/1.6/1.7), and μ-Conotoxin GIIIB at 200 nM (light blue; NaV1.4). (B) Average current density is similar in left and right ventricles but higher in the atria. Data from pooled WT and NaV1.5-GX cardiomyocytes (LV, n=13; RV, n=9; atria, n=18). Mean ± SD; ***, p<0.001; ****, p<0.0001; one-way ANOVA with post-hoc Tukey’s test. (C) Representative diary plots of peak current density and current traces (insets) of sodium currents during cumulative serial application of NaV inhibitors in isolated mouse cardiomyocytes from left ventricle (left), right ventricle (middle), and atria (right). Cells were held at a potential of -80 mV, hyperpolarized to -120 mV for 100 ms, and depolarized to -20 mV for 300 ms to elicit peak currents at 1 Hz in 50 mM Na + external solution. Scale bars in insets represent 5 nA (vertical) and 3 ms (horizontal). Bars above each plot indicate the application of NaV inhibitor at the concentrations described above. Experiments targeting NaV1.4, NaV1.1/1.3, and NaV1.8 in ventricle (middle left, bottom left) were performed in 140 mM Na + external solution in the presence of 500 nM GX-674 at baseline to amplify current from the target isoforms. (D) Estimated percent of the baseline sodium current attributable to each NaV isoform in LV, RV, and atria. Percentages of NaV1.4, NaV1.1/1.3, and NaV1.8 were scaled according to the average non-NaV1.5 and non-NaV1.2/1.6/1.7 current. Mean ± SD. Sample sizes are indicated above each bar. N ≥ 6 mice per heart chamber. (E) Summary of sodium current composition by NaV isoform in LV, RV, and atria. Legend as in panel D.
    Voltage Sensor Toxin 3 Vstx3, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/voltage sensor toxin 3 vstx3/product/Alomone Labs
    Average 90 stars, based on 1 article reviews
    voltage sensor toxin 3 vstx3 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) NaV isoform selectivity of inhibitors GX-674 at 500 nM (orange; NaV1.2/1.6/1.7 and NaV1.5-GX), VSTx3 at 500 nM (green; NaV1.3/1.7/1.8), TTX at 50 nM (dark blue; NaV1.1/1.2/1.3/1.4/1.6/1.7), and μ-Conotoxin GIIIB at 200 nM (light blue; NaV1.4). (B) Average current density is similar in left and right ventricles but higher in the atria. Data from pooled WT and NaV1.5-GX cardiomyocytes (LV, n=13; RV, n=9; atria, n=18). Mean ± SD; ***, p<0.001; ****, p<0.0001; one-way ANOVA with post-hoc Tukey’s test. (C) Representative diary plots of peak current density and current traces (insets) of sodium currents during cumulative serial application of NaV inhibitors in isolated mouse cardiomyocytes from left ventricle (left), right ventricle (middle), and atria (right). Cells were held at a potential of -80 mV, hyperpolarized to -120 mV for 100 ms, and depolarized to -20 mV for 300 ms to elicit peak currents at 1 Hz in 50 mM Na + external solution. Scale bars in insets represent 5 nA (vertical) and 3 ms (horizontal). Bars above each plot indicate the application of NaV inhibitor at the concentrations described above. Experiments targeting NaV1.4, NaV1.1/1.3, and NaV1.8 in ventricle (middle left, bottom left) were performed in 140 mM Na + external solution in the presence of 500 nM GX-674 at baseline to amplify current from the target isoforms. (D) Estimated percent of the baseline sodium current attributable to each NaV isoform in LV, RV, and atria. Percentages of NaV1.4, NaV1.1/1.3, and NaV1.8 were scaled according to the average non-NaV1.5 and non-NaV1.2/1.6/1.7 current. Mean ± SD. Sample sizes are indicated above each bar. N ≥ 6 mice per heart chamber. (E) Summary of sodium current composition by NaV isoform in LV, RV, and atria. Legend as in panel D.

    Journal: bioRxiv

    Article Title: Non-canonical Sodium Channel Isoforms Underlie Chamber Specific Cardiac Excitability

    doi: 10.1101/2025.08.27.672688

    Figure Lengend Snippet: (A) NaV isoform selectivity of inhibitors GX-674 at 500 nM (orange; NaV1.2/1.6/1.7 and NaV1.5-GX), VSTx3 at 500 nM (green; NaV1.3/1.7/1.8), TTX at 50 nM (dark blue; NaV1.1/1.2/1.3/1.4/1.6/1.7), and μ-Conotoxin GIIIB at 200 nM (light blue; NaV1.4). (B) Average current density is similar in left and right ventricles but higher in the atria. Data from pooled WT and NaV1.5-GX cardiomyocytes (LV, n=13; RV, n=9; atria, n=18). Mean ± SD; ***, p<0.001; ****, p<0.0001; one-way ANOVA with post-hoc Tukey’s test. (C) Representative diary plots of peak current density and current traces (insets) of sodium currents during cumulative serial application of NaV inhibitors in isolated mouse cardiomyocytes from left ventricle (left), right ventricle (middle), and atria (right). Cells were held at a potential of -80 mV, hyperpolarized to -120 mV for 100 ms, and depolarized to -20 mV for 300 ms to elicit peak currents at 1 Hz in 50 mM Na + external solution. Scale bars in insets represent 5 nA (vertical) and 3 ms (horizontal). Bars above each plot indicate the application of NaV inhibitor at the concentrations described above. Experiments targeting NaV1.4, NaV1.1/1.3, and NaV1.8 in ventricle (middle left, bottom left) were performed in 140 mM Na + external solution in the presence of 500 nM GX-674 at baseline to amplify current from the target isoforms. (D) Estimated percent of the baseline sodium current attributable to each NaV isoform in LV, RV, and atria. Percentages of NaV1.4, NaV1.1/1.3, and NaV1.8 were scaled according to the average non-NaV1.5 and non-NaV1.2/1.6/1.7 current. Mean ± SD. Sample sizes are indicated above each bar. N ≥ 6 mice per heart chamber. (E) Summary of sodium current composition by NaV isoform in LV, RV, and atria. Legend as in panel D.

    Article Snippet: Inhibitors were acquired from Alomone Labs (Jerusalem, Israel): VSTx-3 (STT-350), μ-conotoxin GIIIB (C-270) and TTX (T-500).

    Techniques: Isolation